Cytochrome P2E1 (CYP2E1) Gene Polymorphism as a Potential Prognostic Biomarker in Colorectal Cancer.
Biomarker
CYP2E1
Colon cancer
Polymorphism
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
received:
05
01
2022
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Colon cancer is the most common type of gastrointestinal cancer. Genetic factors have been shown to have a role in the development of colorectal cancers. The aim of this study was to assess the expression of Cytochrome P2E1 (CYP2E1) gene polymorphism as a potential prognostic biomarker in the diagnosis, treatment, and prognosis evaluation of patients with colorectal cancer. in this cross-sectional study, all of our 100 patients with colorectal cancer who underwent surgical operation were included. DNA was extracted from the tumor specimens to assess Cytochrome P2E1 (CYP2E1) Gene polymorphism by Conventional-PCR. RFLP-PCR method was used for RsaI polymorphism evaluation. Patients' characteristics were also recorded and their associations with CYP2E1 were assessed. One hundred tumor specimens were assessed. In total, 88 had wild-type, 8 had purely a 96 bp insertion in CYP2E1, and 4 were partially mutated by a single allele insertion. Generally, 10% of samples had positive results for the RsaI polymorphism. There were no statistically significant associations between CYP2E1 gene polymorphism and number of lymph nodes removed during the operation (P = 0.353), number of positive lymph nodes (P = 0.668), tumor specificity including mucinous or non-mucinous (P = 0.053), tumor invasion (P = 0.074), grading (P = 0.898), differentiation (P = 0.941), tumor location (P = 0.42) or staging (P = 0.182). There was no association between RsaI type CYP2E1 polymorphism and colorectal cancer risk. Our study does not support the use of this biomarker to evaluate the prognosis of colon cancer.
Sections du résumé
BACKGROUND
Colon cancer is the most common type of gastrointestinal cancer. Genetic factors have been shown to have a role in the development of colorectal cancers. The aim of this study was to assess the expression of Cytochrome P2E1 (CYP2E1) gene polymorphism as a potential prognostic biomarker in the diagnosis, treatment, and prognosis evaluation of patients with colorectal cancer.
METHODS
in this cross-sectional study, all of our 100 patients with colorectal cancer who underwent surgical operation were included. DNA was extracted from the tumor specimens to assess Cytochrome P2E1 (CYP2E1) Gene polymorphism by Conventional-PCR. RFLP-PCR method was used for RsaI polymorphism evaluation. Patients' characteristics were also recorded and their associations with CYP2E1 were assessed.
RESULTS
One hundred tumor specimens were assessed. In total, 88 had wild-type, 8 had purely a 96 bp insertion in CYP2E1, and 4 were partially mutated by a single allele insertion. Generally, 10% of samples had positive results for the RsaI polymorphism. There were no statistically significant associations between CYP2E1 gene polymorphism and number of lymph nodes removed during the operation (P = 0.353), number of positive lymph nodes (P = 0.668), tumor specificity including mucinous or non-mucinous (P = 0.053), tumor invasion (P = 0.074), grading (P = 0.898), differentiation (P = 0.941), tumor location (P = 0.42) or staging (P = 0.182).
CONCLUSION
There was no association between RsaI type CYP2E1 polymorphism and colorectal cancer risk. Our study does not support the use of this biomarker to evaluate the prognosis of colon cancer.
Identifiants
pubmed: 37505752
doi: 10.31557/APJCP.2023.24.7.2239
pmc: PMC10676490
pii:
doi:
Substances chimiques
Cytochrome P-450 CYP2E1
EC 1.14.13.-
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2239-2244Références
Cancer Causes Control. 2013 Jun;24(6):1207-22
pubmed: 23563998
Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1019-24
pubmed: 12376502
Dan Med J. 2012 Apr;59(4):B4428
pubmed: 22459726
Int J Cancer. 2018 Oct 1;143(7):1620-1631
pubmed: 29696648
Anticancer Res. 2007 Jul-Aug;27(4C):2931-7
pubmed: 17695473
Nat Rev Dis Primers. 2015 Nov 05;1:15065
pubmed: 27189416
World J Gastroenterol. 2010 Jun 21;16(23):2949-53
pubmed: 20556843
World J Gastroenterol. 2007 Nov 21;13(43):5725-30
pubmed: 17963298
World J Gastroenterol. 2015 Jun 14;21(22):7014-21
pubmed: 26078580
J Gastroenterol Hepatol. 2001 Jun;16(6):631-5
pubmed: 11422615
Mutat Res. 2006 Jan 29;593(1-2):39-49
pubmed: 16039674
Appl Clin Genet. 2014 Jul 22;7:147-58
pubmed: 25161364
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Dtsch Arztebl Int. 2013 Jan;110(3):32-8
pubmed: 23413378
Int J Mol Sci. 2017 Jan 19;18(1):
pubmed: 28106826
Tumour Biol. 2013 Aug;34(4):2389-95
pubmed: 23595220
Mod Pathol. 2018 Oct;31(10):1608-1618
pubmed: 29884888
Physiol Rev. 1997 Apr;77(2):517-44
pubmed: 9114822
Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008997
pubmed: 22895981
Tumour Biol. 2013 Aug;34(4):2225-31
pubmed: 23636797
CA Cancer J Clin. 2018 May;68(3):217-231
pubmed: 29485237
Tumour Biol. 2012 Apr;33(2):523-35
pubmed: 22161138
Anticancer Res. 2000 Jan-Feb;20(1B):519-22
pubmed: 10769717
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):2806-2811
pubmed: 29490919
Oncotarget. 2017 Sep 18;8(49):86853-86864
pubmed: 29156840
Khirurgiia (Mosk). 2012;(2):4-13
pubmed: 22678468
Hum Genomics. 2011 Oct;5(6):530-7
pubmed: 22155602
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1800-7
pubmed: 18628434
Am J Gastroenterol. 2015 Feb;110(2):223-62; quiz 263
pubmed: 25645574
Chem Res Toxicol. 1991 Mar-Apr;4(2):168-79
pubmed: 1664256
World J Gastroenterol. 2014 Jun 28;20(24):7602-21
pubmed: 24976699